Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
NCT04862234 · Emory University · PHASE4 · terminated · last registry update 2025-01-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This clinical trial was terminated on June 7, 2024 due to new information about contraindications of using the study drug in this population.” | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GLP1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-19Phase 3 first posted: Instituto Mexicano del Seguro Social, Dapagliflozin 10 MG Oral Tablet + Semaglutide (Rybelsus®) (NCT07295223)
- 2025-12-16Phase 3 first posted: Kailera, Ribupatide + Semaglutide (NCT07284979)
- 2025-12-16Phase 3 first posted: McGill University Health Centre/Research Institute of the McGill University Health Centre, Tirzepatide (NCT07284511)
- 2025-12-15Phase 3 first posted: Novo Nordisk A/S, CagriSema (Cagrilintide B and Semaglutide I) + Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (NCT07282613)
- 2025-12-09Phase 3 first posted: Novo Nordisk A/S, Oral semaglutide (NCT07271251)
- 2025-11-28Phase 3 first posted: Novo Nordisk A/S, Cagrilintide + Semaglutide (NCT07253285)
- 2025-11-18Phase 3 first posted: Eli Lilly and Company, Retatrutide + Placebo (NCT07232719)
- 2025-10-20Phase 3 first posted: VA Office of Research and Development, Semaglutide + Placebo (NCT07218354)
- 2025-09-10Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Retatrutide (NCT07165028)
- 2025-07-18Results posted on the registry: Eli Lilly and Company, Bimagrumab + Semaglutide (NCT05616013)
- 2025-07-14Phase 3 first posted: BrightGene Bio-Medical Technology Co., Ltd., BGM0504 + BGM0504 (NCT07064486)
- 2025-07-10Phase 3 first posted: Ottawa Heart Institute Research Corporation, Semaglutide + Nicotine replacement (NCT07059377)
- 2025-07-08Results posted on the registry: Novo Nordisk A/S, Semaglutide + Placebo (semaglutide) (NCT04560998)
- 2025-06-24Phase 3 first posted: Eli Lilly and Company, Retatrutide + Placebo (NCT07035093)
- 2025-06-15Phase 3 first posted: University of Colorado, Denver, Semaglutide 1.7mg subcutaneous + Placebo (NCT07021937)
- 2025-06-09Phase 3 first posted: Novo Nordisk A/S, CagriSema (Cagrilintide B and Semaglutide I) + Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (NCT07011667)
- 2025-05-16Phase 3 first posted: University of Colorado, Denver, Metformin + semaglutide (NCT06975111)
- 2025-04-22Phase 3 first posted: Eli Lilly and Company, Mirikizumab + Mirikizumab (NCT06937086)
- 2025-04-22Phase 3 first posted: Eli Lilly and Company, Mirikizumab + Mirikizumab (NCT06937099)
- 2025-04-18Phase 3 first posted: Children's Hospital Los Angeles, Semaglutide 2.4 mg (NCT06934655)
- 2025-04-06Phase 3 first posted: University Health Network, Toronto, Semaglutide 0.25 mg + Semaglutide 0.5 mg (NCT06913023)
- 2025-03-26Phase 3 first posted: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Metformin with Semaglutide (NCT06896981)
- 2025-01-17Results posted on the registry: Novo Nordisk A/S, IcoSema + Semaglutide 1 mg (NCT05259033)
- 2025-01-16Phase 3 first posted: Gan & Lee Pharmaceuticals., GZR18 + semaglutide (NCT06778967)
- 2024-12-24Phase 3 first posted: Amylyx Pharmaceuticals Inc., Avexitide (NCT06747468)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision